57 results about "Ferritin receptors" patented technology

Enrichment for human Keratinocyte Stem Cells KSCs to a high degree of purity can be successfully achieved on the basis of a cell surface component whose expression is proliferation-related in conjunction with an integrin such as the alpha6beta4 integrin. Transferrin receptor may be used as the cell surface component that is proliferation related. Enrichment of Transit amplifying cells can also be achieved by use of a variation of this method. The enrichment follows on from harvesting of cells from an epithelium, preferably rich in stem cells.

The invention discloses a magnetic nano-grade material with a cell-targeting property, and a biomedical application thereof. The magnetic nano-grade material can be specifically bound with highly expressed transferrin receptors on tissue cell surfaces, and can enter the cells. The material can be bound with various high-transferring-receptor-expression tissue cells with broad spectrum and specificity, such that high-efficiency cell targeting property can be realized on animal models. The material can be used as a magnetic resonance contrast agent and a fluorescent molecular probe in disease diagnosis, and can be used as a medicine carrier in disease treatment.

Nucleic acid-immunoliposome compositions useful as therapeutic agents are disclosed. These compositions preferably comprise (i) cationic liposomes, (ii) a single chain antibody fragment which binds to a transferrin receptor, and (iii) a nucleic acid encoding a wild type p53. These compositions target cells which express transferrin receptors, e.g., cancer cells. These compositions can be used therapeutically to treat persons or animals who have cancer, e.g., head and neck cancer, breast cancer or prostate cancer.

Fusion proteins of transferrin and other therapeutic moieties with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and / or binding to the transferrin receptor.

The invention discloses a nucleic acid aptamer sequence for recognizing and being combined with a human transferrin receptor and application of the nucleic acid aptamer sequence. A nucleic acid aptamer and derivatives thereof can be applied in kits, molecular probes and targeted media for recognizing or preparing and detecting transferrin receptor high-expression tumors and applied in nucleic acid probes for designing, preparing and detecting transferrin receptors. The nucleic acid aptamer has the advantages that the affinity and specificity are higher than those of the prior art, the aptamer is free of immunogenicity, chemical synthesis can be achieved, and the nucleic acid aptamer is small in molecular weight, stable, easy to store and mark and the like.

The invention discloses a docetaxel transferrin acceptor-targeted liposome preparation. The preparation is prepared with a preparation method comprising the following steps of: mixing 55-95 parts by weight of phospholipid, 3-40 parts by weight of cholesterol and 0.05-20 parts by weight of docetaxel; dissolving into ethanol; performing rotary evaporation; adding 0.5-1.5ml of a phosphate buffer solution, and hydrating to obtain a liposome; and connecting a transferrin ligand to a liposome surface which contains docetaxel by applying a backward embedding technology to obtain a docetaxel transferrin acceptor-targeted liposome preparation, wherein the average particle diameter of the preparation is 60-100 nanometers, and the interfacial potential is -10mV to 20mV. As proved by a cytotoxicity research result, compared with a non-targeted liposome, a transferrin acceptor-targeted liposome has the advantage that: the toxicity of docetaxel on KB cells can be enhanced remarkably. The docetaxel transferrin acceptor-targeted liposome disclosed by the invention can become a novel medicament preparation for treatment cancers in future.

An isolated and purified non-denatured transferrin receptor protein of a Moraxella strain, particularly M. catarrhalis, has an apparent molecular mass of about 80 to about 90 kDa, as determined by SDS-PAGE. The transferrin receptor protein or a fragment analog thereof is useful in diagnostic applications and immunogenic compositions, particularly for in vivo administration to a host to confer protection against disease caused by a strain of Moraxella.

Modified fusion proteins of transferrin and therapeutic proteins or peptides with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and / or binding to the transferrin receptor.

Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.

The invention discloses a method for preparing a fluorescent probe with a tumor targeting effect by taking ferritin as a carrier. The ferritin carrier comprises human heavy chain ferritin. The methodcomprises the following steps: depolymerizing the human heavy chain ferritin with a cage-shaped structure into a monomer state; adding coumarin-6 with fluorescent properties into the depolymerized human heavy chain ferritin and combining the coumarin-6 with the ferritin; and re-polymerizing the depolymerized human heavy chain ferritin combined with the coumarin-6 into nanoparticles. The nano probeprepared by the invention has good biocompatibility and can be specifically enriched on the surface of tumor cells of an overexpression transferrin receptor 1(TfR1); and an efficient detection methodis provided for in-vivo tracing of a drug delivery system by utilizing the fluorescent property of the coumarin-6.

Purified and isolated nucleic acid molecules are provided which encode transferrin receptor proteins of Moraxella, such as M. catarrhalis or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce recombinant transferrin receptor proteins Tbp1 and Tbp2 of the strain of Moraxella free of other proteins of the Moraxella strain for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection.

Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.

Provided is a biomarker for detecting colorectal cancer at an earlier stage. A colorectal cancer biomarker for detecting colorectal cancer includes at least one protein selected from 22 proteins, i.e., proteins 1 to 22, or at least one peptide selected from partial peptides of proteins 1 to 22: 1) annexin A11; 2) annexin A3; 3) annexin A4; 4) tenascin-N; 5) transferrin receptor protein 1; 6) glucose transporter 1; 7) complement component C9; 8) CD88 antigen; 9) 78-kDa glucose-regulated protein; 10) alpha-1-acid glycoprotein; 11) matrix metalloprotease 9; 12) angiopoietin-1; 13) CD67 antigen; 14) mucin-5B; 15) adapter protein GRB2; 16) annexin A5; 17) olfactomedin-4; 18) neutral amino acid transporter B(0); 19) tripeptidyl peptidase 1; 20) heat shock-related 70-kDa protein 2; 21) proteasomesubunit alpha type-5; and 22) neutrophil gelatinase-associated lipocalin.